12:00 AM
 | 
Oct 07, 2002
 |  BioCentury  |  Tools & Techniques

ICAAC: Three's company for HIV

All 16 drugs marketed to treat HIV inhibit viral replication either by inhibiting the viral reverse transcriptase or protease. But reports at last week's Interscience Conference on Antimicrobial Agents and Chemotherapy are showing that these two viral targets now have legitimate company.

Though much of the attention at ICAAC was focused on Fuzeon enfuvirtide (formerly T-20) from Trimeris Inc. and partner Roche, the potential of agents targeting other aspects of HIV replication was not lost on conference attendees.

Second-comers

Fuzeon represents the fusion inhibition approach to viral blockade, and if approved would clinically validate the third HIV target - gp41. TRMS (Durham, N.C.) and ROCZ (Basel, Switzerland), which submitted an NDA last month, released more data from Phase III trials showing that Fuzeon is more active in patients sensitive to other anti-retroviral agents (see B14).

They also presented updated data from a Phase I/II study of T-1249, a second-generation fusion inhibitor, which binds a slightly different region of the HIV gp41 protein than Fuzeon and has activity...

Read the full 832 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >